Similarly, gefitinib resistance is linked to enhanced ferroptosis defense mechanisms[122,123], and inhibiting discoidin domain receptor tyrosine kinase 1 and GPX4 can restore ferroptosis and overcome gefitinib resistance in non-small cell lung cancer and triple-negative breast cancer, respectively[122,124]. This evidence concerns the gene GPX4 and triple-negative breast carcinoma.